Oncolytic virus · Kills target cells · developed by Replimune
Vusolimogene oderparepvec is a genetically modified herpes simplex type 1 (HSV-1) oncolytic virus that infects and replicates in tumor cells, causing their lysis and releasing tumor-associated antigens that stimulate an anti-tumor immune response. It is studied in cutaneous squamous cell carcinoma, Merkel cell carcinoma, basal cell carcinoma, melanoma and angiosarcoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06264180 | Phase 3 | Advanced Melanoma | Recruiting | REPL |
| NCT06898970 | Phase 2 | Angiosarcoma | Recruiting | REPL |
| NCT04349436 | Phase 1/2 | Merkel Cell Carcinoma | Active not recruiting | REPL |
| NCT04050436 | Phase 2 | Cutaneous Squamous Cell Carcinoma | Active not recruiting | REPL |
| NCT06216938 | Early Phase 1 | Melanoma | Recruiting | REPL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Cutaneous Squamous Cell CarcinomaAdvanced MelanomaAngiosarcomaAngiosarcoma, AdultBasal Cell CarcinomaCancerCutaneous Squamous Cell CarcinomaLocally Advanced Cutaneous Squamous Cell CarcinomaMelanomaMerkel Cell CarcinomaMetastatic Cutaneous Squamous Cell Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the REPL page.
See REPL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REPL catalysts and pipeline →